Top Ten most popular articles on Pharmafile this week
pharmafile | December 2, 2016 | News story | Medical Communications |Â Â November, news, pharmaceutical, top 10, top ten, top ten storiesÂ
This week has been an interesting one for pharmaceutical innovation. A number of stories and studies have arisen about trialling and using drugs more often associated with illegal activity rather than with therapeutic aims. Read here to catch up on these stories and the other biggest articles that have been viewed on our website.
10. Illegal psilocybin shows promise in treatment of depression
A double-blind study of psilocybin, the hallucinogenic drug chemical found in ‘magic mushrooms’, has been found to have substantial mental health benefits in those suffering from life-threatening cancer diagnosis.
9. NICE recommends GSK’s “first-in-class” asthma drug
NICE has announced its recommendation of GSK’s biologic Nucala (mepolizumab) as an extra option for the treatment of adults suffering from severe forms of asthma.
8. Researchers develop capsule-based haemophilia treatment tech
Researchers at the University of Texas have developed a new method for treating haemophilia B which utilises a biodegradable oral delivery system.
7. Real world evidence: a reality check for pharma?
Rising demands on the industry has pharma firms calling for a more-effective, fit-for-purpose methodology for generating clinical data. Could the answer be real world evidence?
6. Takeda gains marketing authorisation for multiple myeloma pill
Takeda has gained conditional marketing authorisation from the European Commision for its drug Ninloma. Once it reaches market, it will be the first and only oral pill available for this kind of treatment.
5. MDMA trials get FDA backing for PTSD treatment
The FDA have given the go-ahead to Phase 3 clinical trials investigating the efficacy of MDMA for treating post-traumatic stress disorder.
4. Pfizer scraps €400m Dublin facility expansion
Pfizer has U-turned on the expansion of its Grange Castle, Dublin facility in a 34,500 square-metre expansion that was to create 350 jobs.
3. Patheon acquires state-of-the-art manufacturing facility from Roche
Patheon, a provider of drug development and delivery to the pharmaceutical and biopharma sectors, announced that it has acquired a state-of-the-art manufacturing facility from Roche.
2. Biosimilars and Generics: A no-brainer for treatment?
The industry is poised on the potential widespread adoption of many revolutionary technologies; foremost among them are biosimilars and generics, alternatives to traditional treatment which promise to keep costs low and healthy patients high.
1. Teva to market world’s first medical marijuana inhaler
Israel’s Teva Pharmaceutical Industries has signed an agreement with Tel Aviv-based biotech Syqe Medical for the distribution and marketing of the world’s first medical cannabis inhaler.
Related Content
FlyPharma Europe, Vienna – 23-24 October 2024 conference
Samedan announces that on 23-24 October 2024, their FlyPharma Conference will make a welcome return …
FDA release statement exercising caution around dosing errors associated with compounded injectable semaglutide products
This week, the US Food and Drug Administration (FDA) and have issued warnings regarding dosing …
Zumutor’s cancer drug trial cleared by FDA
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …
